Brigham Young University

BYU ScholarsArchive
All Theses and Dissertations

2016-12-01

Control of Matrix Metalloproteinases in a
Periodontitis Model: Molecules That Trigger or
Inhibit MMP Production
Catalina Matias Orozco
Brigham Young University

Follow this and additional works at: https://scholarsarchive.byu.edu/etd
Part of the Chemistry Commons
BYU ScholarsArchive Citation
Matias Orozco, Catalina, "Control of Matrix Metalloproteinases in a Periodontitis Model: Molecules That Trigger or Inhibit MMP
Production" (2016). All Theses and Dissertations. 6242.
https://scholarsarchive.byu.edu/etd/6242

This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in All Theses and Dissertations
by an authorized administrator of BYU ScholarsArchive. For more information, please contact scholarsarchive@byu.edu, ellen_amatangelo@byu.edu.

Control of Matrix Metalloproteinases in a Periodontitis Model:
Molecules That Trigger or Inhibit MMP Production

Catalina Matías Orozco

A dissertation submitted to the faculty of
Brigham Young University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy

Richard K. Watt, Chair
Joshua Andersen
David M. Belnap
Chad Hancock
Dixon Woodbury

Department of Chemistry and Biochemistry
Brigham Young University

Copyright © 2016 Catalina Matías Orozco
All Rights Reserved

ABSTRACT
Control of Matrix Metalloproteinases in a Periodontitis Model:
Molecules That Trigger or Inhibit MMP Production
Catalina Matías Orozco
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
In periodontitis, there is a disruption in the homeostasis of the oral microbiome
by peridontopathogenic bacteria. However, while bacteria is essential for periodontitis
to occur, the severity, pattern and progression of the disease is not solely determined by
the microbial burden, and in fact has a lot to do with the overwhelming host
inflammatory response. The response can vary even in two individuals with similar
periodontopathogenic profiles. The host response leads to extracellular matrix (ECM)
destruction, loss of attachment, alveolar bone resorption and eventually, edentulism.
The host’s reaction is orchestrated by proinflammatory cytokines and chemokines and
matrix metalloproteinases (MMPs). MMPs are proteolytic enzymes capable of
degrading collagen fibers from the extracellular matrix and are the main responsible for
tissue damage and gingival recession in periodontitis.
As a response to the limitations of the traditional therapies, new agents have
been used in preclinical and clinical studies, namely host-modulatory agents, including
anti-proteinase agents, anti-inflammatory agents and anti-resorptive agents. Focusing
on changing the inflammatory process, as opposed to the microbial insult, can slow
down the disease progression, improve clinical outcomes and even prevent tooth loss in
severely compromised patients.
This work examines the role of pro-inflammatory markers homocysteine in
chronic inflammation and periodontitis. Homocysteine (Hcy) is a non-protein amino
acid derived from the metabolism of the essential amino acid methionine via methyl
group metabolism. Controlling Homocysteine as a potential inductor of MMPs, and
hence of tissue destruction, can lead to new adjuvant therapies to improve clinical
outcomes and prevent activation of the disease
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Chapter 1 Introduction to Periodontitis

Periodontitis is a dysbiotic inflammatory disease that disrupts the periodontium
that comprises the structures offering support to the teeth, such as gingiva, periodontal
ligament and alveolar bone (Figure 1.1)1. It is immediately preceded by gingivitis, but
bacterial accumulation is such that it results in a host response that ultimately leads to
tissue destruction.

Figure 1.1 Healthy vs. Diseased periodontium. The periodontium is composed by specialized tissues
that surround and support the tooth, including the gingiva, periodontal ligament, alveolar bone and
cement. Periodontitis arises when the oral microbiota switches from a commensal community into a
pathogenic one. The periodontopathogenic bacteria elicit a host response that self-perpetuates and leads
to chronic inflammation and destruction of the periodontium tissues and tooth loss.
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Periodontitis became prevalent after the switch in diet from the hunter-gatherer
communities of the Mesolithic era into the farming Neolithic communities (~10200 BC).
The increased consumption in fermentable carbohydrates (such as wheat and barley)
led to the perturbation of a healthy, ecologically balanced oral biofilm and therefore, the
accumulation of oral plaque that mediate polymicrobial infections2. Oral biofilms are
readily evident when analyzing plaque from early European skeletons. Modern oral
flora seems to be less diverse than that of historic populations, increasing susceptibility
to caries and periodontal disease3,4.

In the past two decades periodontitis has been recognize as public health matter
of the utmost importance, as oral health mirrors social inequalities5,6. Periodontitis
affects the quality of life as a result of low self-esteem, pain, tooth loss, missing school
and work hours, impaired oral function and disfigurement7–11. Figures estimate that
periodontitis affects over 50% of the adult population, while severe forms of
periodontitis affect 11% of the adults, making severe periodontitis the sixth most
prevalent disease in the world9. According to 2012 figures, periodontitis is present in
47.2% or 64.7 million adults in the United States. The percentage increases to 70% in
people 64 years and older12. Periodontal disease can also affect children and
adolescents, especially those with systemic illnesses13,14. The economic burden of
periodontitis accounts for a significant allocation of the US $442 billion spent in oral
healthcare in 201015.
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Epidemiologic figures are especially alarming when one considers the
association between periodontitis and cardiovascular disease, discovered in recent
years16–18. Periodontitis has been associated with other systemic inflammatory illnesses
such as rheumatoid arthritis, cardiovascular disease, diabetes, adverse pregnancy
outcomes, cancer, aspiration pneumonia and chronic obstructive pulmonary disease
(COPD)19–32.

Risk factors of Periodontal disease

There are several well-established risk factors for periodontal disease. These have
been extensively reviewed elsewhere, yet we will summarize them concisely for better
understanding of the disease.

Lifestyle factors

The most prevalent risk factor is being male. This difference can be attributed to
a lifestyle and not to an inherent susceptibility to the disease. Knowing this, males
should be targeted for preventive measures and more aggressive interventions33.

Smoking is the most well known risk factor for periodontal disease. Studies have
shown that oral hygiene is poor in smokers and that severity and incidence of
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periodontitis is also correlated to the number of pack-years smoked. Possible
mechanisms for the adverse effects of smoking include decreasing gingival blood flow,
cytokine production, polymorphonuclear neutrophil (PMN) phagocytosis and positive
selection of specific periodontal pathogens34,35.

Smoking cessation reduces the probability of developing periodontitis and
improves the microbiological profile, while failure to stop smoking during periodontal
treatment can impair healing of the periodontal wound and contribute to loss of
attachment and edentulism35–37.

Alcohol consumption has also been linked with increased incidence of
periodontal disease, mainly due to worsening of the microbiological profile and
increased interleukin-1β (IL-1β). Concomitant use of alcohol and cigarettes has a more
profound effect in oral health38,39.
Systemic illnesses

Diabetes has shown a two-way relationship with the development and severity
of periodontitis. In diabetic patients, there is already an up-regulation of several
inflammatory processes, oxidative stress and apoptosis. These patients also present
with higher levels of IL-1β and prostaglandin E2 in the gingival crevicular fluid (GCF),
thus worsening the extent of the disease40,41.
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Cardiovascular and cerebrovascular disease have also been linked to a higher
risk of periodontitis, possibly due to the fact they share many common mechanisms and
inflammatory intermediates20,42,43. Many of the habits and chronic illnesses associated to
cardiovascular disease are also positively correlated with periodontitis. Periodontal
treatment initially increases serum levels of inflammatory biomarkers and worsens
endothelial function. A few weeks after treatment, both parameters show considerable
improvement when compared to pre-treatment status44.
Obesity is also a risk factor for periodontitis, explained mostly to a difference in
dietary patterns that favor consumption of sugary and carbonated drinks over calcium
and vitamin C45.
Osteoporosis

Osteoporosis is characterized by a reduced bone density, which increases the risk
of fractures and death in the elderly. The decreased calcium absorption and increased
calcium excretion present in osteoporosis have a significant impact in morbidity and
mortality. Because of the bone loss, osteoporosis presents itself with severe alveolar
crest height and mandibular atrophy exacerbating tooth loss in periodontal patients46.
The mandibular atrophy puts patients at risk for implant failure, limiting treatment
options33,47. Interestingly, bisphosphonates, which are a standard therapy for
osteoporosis, are effective in reducing alveolar bone loss and can reduce tooth loss47.
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Stress

Some studies have described psychological stress and ineffective coping
mechanisms as contributors to chronic periodontal disease33. Severity of stress has been
positively correlated to intensity of the disease and attachment loss. People with
problem-focusing coping seemed to fare better than passive copers regarding
progression of the disease48. The studies suggested that this effect is due to the stress
response, such as sympathetic nervous system activation and production of
glucocorticoid hormones from the adrenal cortex49,50. Stress can also trigger unhealthy
behaviors, such as poor oral hygiene, increased smoking, fewer dental checkups and
altered eating habits.

Etiology

The precursor event to periodontitis is the progressive buildup of dental plaque.
The plaque biofilm is a stable bacterial community formed in teeth, mucosa, or other
solid surfaces51. The bacterium attaches to the tooth surface and begins to grow,
producing adhesins and extracellular polymers that enable the growth of more bacteria.
Eventually, the diffusion of nutrients and oxygen throughout the biofilm is limited,
favoring anaerobic bacteria. Different communities can be established in different sites,
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and the progressive tartar buildup elicits a host response that develops into
periodontitis52.

The current agreement is that periodontitis results from a polymicrobial synergy
that disturbs the otherwise ecologically balanced biofilm19,53,54. Traditionally, the socalled red complex formed by Porphyromonas gingivalis, Treponema denticola and
Tannerella forsythia was considered the climax of the biofilm formation in sites with
active periodontitis55. While an in-depth discussion of the oral biofilms is not the
objective of this review, it is important to mention that the oral microbioma is more
diverse than it was originally thought56. With the aid of newer molecular biology
techniques it is possible to identify over 700 different species present as oral microbiota.
A good number of these microorganisms can correlate just as strongly as P. gingivalis
with the development of periodontitis. The diversity in the microorganisms includes
gram- positive bacteria, such as Filifactor alocis, Megasphere, Desulfobulbus, Selenomonas
sputigena, Actenomyces naeslum, Sreptococcus spp and Peptostreptococcus spp, and gramnegatives

such

as

Aggregatibacter

actinomycetemcomitans,

Campylobacter

spp,

Fusobacterium nucleatum, Eubacterium spp, Bacteroides spp, Prevotella spp and Treponema
spp57–60. The predominant habitat for the periodontopathogenic bacteria is the
subgingival crevice that includes the tooth-associated biofilm, the gingival crevicular
fluid (GCF) and the gingival epithelial cells (GECs)54.
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Bacterial insult in periodontitis

To maintain oral health, the normal microbiota must keep the dental plaque in
check. Host immunoregulatory defects or subversion by the microbial community can
make the host ineffective at restraining bacterial outgrowth and overt pathogenicity.
The homeostasis is disrupted and the poorly controlled host response establishes a selfperpetuating, positive feedback loop, in which dysbiosis and inflammation reinforce
each other. Despite of the diversity of the microbial community, the extensive study of
P. gingivalis as the keystone pathogen has permitted researchers to create a model for
the dysbalanced host response19,61.

P. gingivalis main role is to trigger the conversion of a symbiotic community into
a dysbiotic one, capable of eliciting the host’s response62. A few virulence factors help P.
gingivalis (and other bacteria) to achieve this goal such as gingipains, lipopolysaccharide
lipid A and the bacterial DNA.

The host responds in turn by activating an

inflammatory cascade (Figure 1.2), recruiting inflammatory cells, antibodies and release
of inflammatory cytokines and matrix metalloproteinases (MMPs)63

P. gingivalis and lipopolysaccharide
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Lipopolysaccharide (LPS) is the major macromolecule found on the outer surface
of the gram-negative bacteria. The lipid anchor domain of lipopolysaccharide, Lipid A,
is present in the outer leaflet of the outer membrane of the bacteria. Lipid A is essential
for maintaining the structural integrity of the bacteria and for creating a barrier that
selectively limits the entry of hydrophobic molecules and toxins64. P. gingivalis is
capable of synthesizing a heterogeneous population on lipid A molecules, which in turn
can elicit different immune responses. LPS, and more specifically, lipid A, acts mainly
via a Toll-like receptor 4 (TLR4), triggering a pro-inflammatory cytokine-producing
cascade65. Human Gingival Fibroblasts (HGF) are the most abundant resident cells in
the periodontal tissue and constitutively express TLR4 and TLR266,67. These receptors,
particularly TLR4, present along with CD14 and MD2 on the surface of the HGFs.
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Figure 1.2 Inflammatory cascade in periodontitis. Lypopolysaccharide from P. gingivalis activates an
inflammatory cascade upon binding to Toll-like receptor 4 (TLR4). Complement C3a or C5b can be
synergistically activated with TLR4, resulting in an enhanced activation of MAPK and the transcriptional
factors nuclear factor κB (NF-κB) and activator protein-1 (AP-1). This combined effect could magnify the
inflammatory response and increase cytokine production.

Upon stimulation by LPS, TLR4 initiates the interaction between the receptor
domains and the cytoplasmic adaptor molecules, specifically myeloid differentiation
primary response protein-88 (MyD88). In turn, MyD88 activates interleukin 1-receptor
associated kinase (IRAK), which associates with tumor necrosis factor-associated
receptor 6 (TRAF6) (Figure 1.2). This can lead to the activation of activator protein-1
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(AP-1) through mitogen activated protein kinase (MAPK) or the transforming growth
factor-β-activated kinase/ transforming growth factor-β-activated kinase binding
protein, enhancing the activity of nuclear factor-κ-B kinase (NF-κB) complex that
translocates into the nucleus to induce the expression of cytokines and chemokines such
as interleukin-1, -6, -8, -12 (IL-1, IL-6, IL-8, IL-12) and tumor necrosis factor-α (TNF-α)68.
Interestingly, HGF do not develop resistance to LPS over time and are key in sustaining
the inflammatory response in periodontal disease66.

P. gingivalis and gingipains

The gingipains or cysteine proteases carry out most of the proteolytic activity of
LPS. Arginine-specific proteinases RgpA and RgpB and the lysine specific proteinase
Kgp represent the majority of the cell-surface proteinases in P. gingivalis. These enzymes
can halt host defenses by degrading immunoglobulins and complement factors
effectively hijacking some of the host’s defense mechanisms69–71. In the complement
cascade, RgpA will bind the C4b-binding protein, hindering the deposition of the
membrane attack complex on the P. gingivalis surface. While the mechanism in which
this occurs is beyond the scope of this review, the arginine-specific proteases are much
more effective at attacking multiple intermediates in the complement cascade and
eliciting the production of inflammatory cytokines72. More relevant to this review is that
gingipains can directly activate the zymogen form of some MMPs, including MMP-1
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and MMP-873,74. Briefly, gingipains could also be able to increase the expression of
MMP-1 over their endogenous counterpart, the tissue inhibitors of matrix
metalloproteinases (TIMPs). Both events can occur in human periodontal ligament cells
and human gingival fibroblasts73–76.
Host response

P. gingivalis and neutrophil recruitment

Even in the absence of periodontitis, there will be some leukocyte infiltration in
the periodontium because of the close and constant microbial challenge that the oral
biofilm presents. In this instance the role of the neutrophil is a protective one, as it
prevents further invasion into the underlying tissue77. In a diseased state, massive
amounts of neutrophils infiltrate the gingival connective tissue, the junctional
epithelium and the periodontal pocket78–80.

Bacterial challenges prime neutrophils to infiltrate the tissues in an attempt to
destroy the offending microorganism81. The adhesion cascade that makes neutrophil
extrafiltration possible consists of activated endothelial cells expressing E- and Pselectins that interact with the glycoproteins present in the neutrophil surface77,82,83.
Integrins present on neutrophils undergo chemokine-mediated activation leading to
rolling, crawling, adhesion and transmigration of neutrophils into the peripheral
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tissue84.

Once in the peripheral tissue the neutrophils follow a gradient of

chemoattractants to the site of infection. The chemoattractants can be derived from
infecting bacteria, such as LPS or N-formyl-methionyl-leucyl-phenylalanine (fMLP) or
from local complement activation (C5a fragment)85.
To achieve pathogen control in the site of infection, neutrophils have substantial
bag of tricks at their disposal: phagocytosis, reactive oxygen species (ROS), intracellular
and extracellular degranulation and the recently described, neutrophil extracellular
traps (NETs)86,87. In the NETs, web-like structures of decondensed chromatin are
released by mature neutrophils, following activation by TLRs and cytokine receptors.
Several periodontopathogens as well as LPS, TNF-α, IL-1β and IL-8 can stimulate the
release of NETs. This seems to be a good strategy to contain pathogens that cannot be
eliminated with phagocytosis88,89. They have also been proposed to activate T-cell
specific immunity90, but at the same time to activate the secretion of proinflammatory
molecules that damage periodontal tissues91.

Ultimately, in periodontitis, the neutrophil response is incapable of controlling
bacterial growth and the inflammatory response is propagated. Neutrophils then recruit
Th17 cells which in turn recruit more neutrophils, creating a self-perpetuating vicious
cycle92,93. Even if neutrophils can become damaging, individuals unable to effectively
recruit leukocytes to the periodontium for the initial response suffer from aggressive
periodontitis78.
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Despite their beneficial roles, neutrophils granules contain MMP-8, which is
released into the extracellular matrix (ECM) and the GCF during degranulation. In the
ECM, MMP-8 can degrade collagen and lead to gum recession and periodontal
ligament damage94–97. The salivary levels of MMP-8 correlate directly with the severity
of periodontitis98,99.

Matrix Metalloproteinase production

Matrix metalloproteinases are responsible for tissue damage in periodontitis and
can also activate bone resorption mechanisms. They will be discussed at length in the
following chapter.

Conclusions

Periodontitis is initiated by a dramatic shift in oral microbiota, favoring the
survival of periodontopathogenic bacteria. While the presence of bacteria is necessary
for periodontitis, the progress and recurrences of the disease are related to an
uncontrolled, self-perpetuated host inflammatory response. Due to its chronic nature,
inflammation originated in the gingiva leads to systemic inflammation and increases
the patients’ risk for endothelial dysfunction, rheumatoid arthritis, diabetes and adverse
pregnancy outcomes.
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Treatment of periodontitis may initially worsen periodontitis due to the higher
concentration of pathogens and inflammatory molecules in the bloodstream. Overall,
periodontitis has a positive effect over systemic inflammation a few weeks posttreatment. Deep knowledge of the inflammation cascade involved will allow for
targeted, early therapy, preventing adverse events, recurrences and improving clinical
outcomes.
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Chapter 2 Matrix Metalloproteinases: The henchmen of periodontitis

History

A good portion of the tissue damage in periodontal disease can be attributed to
the effect of matrix metalloproteinases (MMPs). MMPs are calcium-dependent zinccontaining endopeptidases, initially discovered by Gross and Lapiere in 1962, because
of their collagenolytic activity in fins explants from tadpoles1. From then on, they
became known as the culprit proteins for ECM degradation. The discovery of the
endogenous inhibitors of the MMPs followed shortly after, in 1975, when Bauer et al.
and Woolley et al. described the expression of pro-collagenase and a collagenase
inhibitor in normal human skin fibroblasts2,3.

Over 50 years have passed since the discovery of MMPs and the human MMP
family has 23 recognized gene members that encode proteins able to cleave a variety of
ECM protein substrates.

The MMP family (also known as matrixins) joins the

membrane-anchored disintegrin metalloproteinases (ADAMs) and meprins in the
larger Metzincin clan. In addition to their canonical function in ECM remodeling,
including embryonic development, wound healing and even tumor invasion roles,
metalloproteinase activity is now linked to the control of immune responses. This can
be done through post-translational modification of proteins and activation of signal
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transduction pathways that control cytokine biosynthesis and direct systemic
inflammation or barrier immunity4–8
Metalloproteinase structure

Humans express 24 matrixin genes, including a duplicated MMP-23 gene for a
total of 23 human MMPs. They do not follow a strict numerical order, with MMP-4,
MMP-5, MMP-6 and MMP-22 missing from the list, as they had been discovered to be
identical to other members9.

Signal peptide

Previously referred as the pre-domain, it consists of a positively charged Nterminal segment, followed by a hydrophobic section of approximately 20 amino
acids10. This section interacts with the signal recognition particle (SRP) and eventually
with the signal recognition peptide receptor to guide the peptide to its predetermined
destination, like the endoplasmic reticulum for the eventual export from the cell.
Mutations that disrupt the interaction of the signal peptide with the SRP interfere with
protein trafficking, and are associated with disease11.

Propeptide domain
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It consists of 80-90 amino acids and contains a cysteine residue, which interacts
with the catalytic zinc atom via the side chain thiol groups12. This cysteine is know as
the “cysteine switch” and ligates the catalytic zinc to maintain latency of the pro-MMP.
All members of the MMPs family are produced as zymogens and removal of the
propeptide domain results in the activation of the proenzyme.
Catalytic domain

Consists of approximately 170 amino acids with two zinc ions and at least one
calcium ion coordinated to various residues. This domain is highly conserved amongst
the MMPs, with sequence similarity between 56 and 64%, while exhibiting a high
degree of functional specificity9,13. One the zinc ions must be present in the catalytic site,
so as to ensure the proteolytic activity of the MMP. The active site is shallow, composed
of three α-helices and a five-stranded twisted β-sheet14.

In the membrane anchored MMPs there is an additional loop formed by 8
residues termed the “MT-Loop” that confers the membrane-anchored MMPs the ability
to activate MMP-2. Additionally, the MT-Loop in MMP-14 (MT1-MMP) influences its
ability to produce cancer cell invasion15

Hinge/Linker region
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This region varies in length with different MMPs and can be as short as 15
residues to as long as 65 residues. It facilitates proper enzyme function by permitting
contact between the catalytic and the hemopexin domain, stabilizing the arrangement
between the MMP and its substrate16.

Hemopexin-like domain (PEX)

This four-bladed β-propeller structure contains three ions, Ca+2, Na+ and Cl-,
which may be crucial for structure stabilization. The hemopexin domain has shown to
be essential for the substrate recognition of some of the MMPs, such as MMP-2. In case
of deletion of its hemopexin domain, MMP-2 retains the catalytic activity against small
peptides like casein, but loses its collagenolytic activity completely17. In recent years,
hemopexin has become a therapeutic target as a method to exploit the interaction with
the substrate18–20.

Furin-cleavage site

This stretch of about 9 residues includes the sequence RXKR/RRKR that allows
for intracellular cleavage by furin. It is not present in all of the MMPs, mainly MMP-11,
-14, -15, -16, -17 and -2721. Some MMPs lack the furin-cleavage-site, and are secreted in a
latent state to be activated by external proteases or even by other MMPs.
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Classification

MMPs were originally classified based on their known substrates, chromosomal
region and sequence similarity. They have been renamed under a number designation,
but some still have not been identified (Table 1.1).

As it is evident from their

substrates, MMPs have a vast proteolytic potential that if left uncontrolled can alter the
functional characteristics of tissue.
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Group

Collagenases

MMPs

Substrate

MMP-1

Types I, II, III, VII, X, XI collagens, gelatin, entactin, tenascin vitronectin, proTNF-β, proMMP-1, proMMP-2,
proMMP-9, Monocyte chemoattractant protein (MCP)-1, MCP-3, MCP-9, CXCL5, CXCL11,

MMP-8

Types I, II, III, VII, X collagens, gelatin, aggrecan, entactin, tenascin, tissue factor pathway inhibitor

MMP-13

Types I, II, III, IV, VI, VII, IX, X, XIV collagens, gelatin, fibronectin, entactin, tenascin, aggrecan, proMMP-9

MMP-18

Types I, II, III, VIII and X collagens, gelatin, aggrecan

MMP-2

Types I, III, IV, V, VII, X, XI collagens, gelatin, elastin, laminin, fibronectin, vitronectin, tenascin, aggrecan,
proTNF-β, proIL-1β, β-antichymotrypsin, insulin-like growth factor binding protein, MMP-1, MMP-9, MMP-13

MMP-9

Types I, IV, V, VII, X, XI, XIV, XVII collagens, gelatin, elastin, laminin, fibronectin, vitronectin, tenascin, aggrecan,
proTNF-α, proIL-1β, β-antichymotrypsin, plasminogen

MMP-3

Types III, IV, V, IX, X, XI collagens, elastin, laminin, fibronectin, proteoglycans, fibrin/fibrinogen, vitronectin,
aggrecan, proTNF-α, proIL-1β, E-cadherin, plasminogen, ovostatin, casein, osteonectin, MMP-7, MMP-8, MMP-9.

MMP-10

Types III, IV, V, IX, X, XI collagens, laminin, fibronectin, proteoglycans, fibrinogen, gelatin, aggrecan, vitronectin

MMP-11

α1-PI, α2-macroglobulin, plasminogen activator inhibitor 2, α2-antiplasmin

MMP-7

Elastin, proteoglycans, laminin, fibronectin, gelatin, types I, III, IV, V, IX, X, XI collagens, fibrin/fibrinogen,
vitronectin, pro-α-defensin, E-cadherin, decorin, plasminogen, proTNF-α, α1-PI

MMP-26

Fibronectin, fibrinogen, type IV collagen, α1-PI, laminin

MMP-14

Type I, II, III collagens, gelatin, casein, κ-elastin, laminin fibronectin, vitronectin, proteoglycans, large tenascin-C,
entactin, aggrecan, α-1-PI, α-2macroglobulin, CD44, transaglutaminase, proMMP-2, proMMP-13

MMP-15

Fibronectin, large tenascin-C, entactin, laminin, aggrecan, perlecan, transaglutaminase, MMP-2

Gelatinases

Stromelysins

Matrilysins

Membranetethered

MMP-16

Type III collagen, gelatin, casein, fibronectin

MMP-24

Type I collagen, gelatin, fibronectin, laminin

MMP-25

Type IV collagen, gelatin, fibronectin, fibrin

Macrophage
Metaloelastase

MMP-12

Enamelysin

MMP-20

Type IV collagen, gelatin, elastin, casein, fibronectin, vitronectin, laminin, entactin, fibrinogen, fibrin, plasminogen
Amelogrenein, aggrecan

Table 2.1 MMP Classification and substrates. Originally named under the belief each MMP had a specific substrate, modern nomenclature has
been revised to reflect the order of discovery. Some designations (MMP-4, MMP-5 and MMP-6) are not used because each represents a gene
product, which was previously given a different MMP number. Tumor necrosis factor (TNF), monocyte chemoattractant protein (MCP),
chemokine C-X-C ligand (CXCL), interleukin (IL), alpha-1 protease inhibitor (α1-PI). Adapted from Lynch and Matrisian, 2002; Zitka, et al.,
201022,23
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Regulation of MMPs

MMPs are regulated at a transcriptional and post-transcriptional level. This
regulation

includes

enzyme

activation,

inhibition,

complex

formation

and

compartmentalization. While most of the MMPs are secreted, and function in an
extracellular environment, they are also located inside the cells, including nucleus,
cytosol and organelles.

The expression of most MMPs is controlled at a transcriptional level, although
the factors controlling the expression of specific MMPs are still a matter of discussion.
Several external factors do play a role on the transcriptional activation, including TGFβ1, TNF-α, IL-1β, endothelial growth factor (EGF), several interferons and
prostaglandin A2. MMPs levels are normally low in tissues, and they increase when
ECM remodeling is required.

The MMP promoters also harbor several cis-elements to regulate gene
expression.

These cis-elements can be shared among similar promoters, and as a

consequence, several MMPs are co-regulated. It is noteworthy that the promoters of
functionally related MMPs, such as the collagenase or gelatinase group, are distinct24.
The diverse set of trans-activators include AP-1, PEA3, Sp-1, β-catenin/Tcf-4 and NF-κB.
Interestingly, MMP-2 is widely expressed in apparently quiescent tissues, and the
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regulation of the proenzyme form and the inhibition of the active enzyme might be
more important.
Naturally occurring polymorphisms are widely spread in the human genome. If
they occur in the promoter region, they can alter the interaction between transcription
factors and cis-elements in the promoters24.

Hypomethylation also contribute to the epigenetic regulation of gene expression
in MMPs, particularly MMP-9, although this might be related to the lack of studies in
other MMPs25,26. Chromatin remodeling and histone modifying enzymes modulate the
access of the promoter to the transcriptional machinery. Taken all together, the
epigenetic mechanisms are a promising area of study to further the understanding of
activation and repression of inducible MMP gene expression27.

Proenzyme activation

Activation of the proMMPs requires the physical delocalization of the prodomain
from the catalytic site. The traditional model of the cysteine switch suggests that there is
a highly conserved cysteine residue in the proenzyme domain of each proMMP28. This
Cys residue is coordinated with the zinc ion in the active site and its dissociation
exposes the active site, and activates the enzyme. The initial proteolytic attack, a
common step in the proMMP activation, occurs at an exposed loop region between the
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first and second helices of the propeptide. This initial attack destabilizes the rest of the
propeptide and the cysteine-zinc interaction, allowing for further processing by
additional intermediates or other MMPs29.

The membrane-anchored MMPs (MMP-14, -15, -16) contain two sets of basic
motifs in the propeptide region that potentially can be recognized by the proprotein
convertase family of subtilisin-like proteases, such as furin30. After activation, MMP-14
can cleave proMMP-2 into the inactive intermediate that is auto catalytically processed
into the fully active, 62 kDa MMP-231.

Compartmentalization

Compartmentalization refers to the regulated process that encloses a MMP in the
pericellular environment as a mechanism to regulate the substrate specificity of the
proteinase32. Despite their extracellular function, cells do not release MMPs
indiscriminately. Specific cell-MMP interactions have been described in the past few
years, such as the binding a MMP-2 and MMP-9 to others ECM molecules, such as
integrin αVβ3 and proteoglycans33,34 or binding to a cell surface glycoprotein, such as
CD44 as a way to get easy access to substrates35. It is possible that these interactions
contribute to MMP functionality, as it is in the case of MMP-9 being recruited to
fibroblast surface to trigger TGF-β activation and fibroblast differentiation36. These
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interactions could facilitate proenzyme activation and substrate cleavage37. In addition
to this, MMPs can be confined to specific secretion vesicles, although the role and
activation of the proenzyme within the same vesicle is still a matter of debate32.

Endogenous inhibitors of MMPs

In order to keep the equilibrium, the proteolytic activity of the MMPs is
regulated by four endogenous inhibitors designated as Tissue inhibitors of
metalloproteinases (TIMPs, TIMP-1 – TIMP-4)38. TIMP-1 is a poor inhibitor of MMP-14,
MMP-16, MMP-24 and MMP-19, and TIMP-3 can inhibit ADAMs and ADAMs with
thrombospondin motifs (ADAMTSs) as well as MMPs9. These highly conserved
proteins inhibit MMP activity by inserting a conserving anchor in the active site of the
target MMP39. The chelation of the catalytic zinc ion from the MMP is essential to
achieve inhibition40,41. Any modifications in the TIMPs that weaken the metal ion
chelating ability, such as the addition of Ala at the N-terminus or carbamylation of the
N-terminal amino group, render the molecule inactive42,43.

The balance between metalloproteinases and TIMPs controls more than ECM
proteolysis. Due to their role in the activation of biologically active proteins, such as
cytokines, chemokines, growth factors and cell surface proteins, the MMP/TIMP axis
also has an effect on the ECM turnover44. This is evident in Timp1-/- mice, which present
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increased ventricular wall stress due to decreased myocardial fibrillar collagen (ECM
proteolysis) and enhanced inflammation following lung injury (ECM turnover). While
the function varies slightly with each TIMP, the dichotomy of their roles must be kept in
equilibrium.

Matrix Metalloproteinases and their role in periodontitis

In the normal periodontium, MMPs have low rates of expression and activity in
order to carry out normal remodeling functions45. Type I collagen forms most of the
ECM in the periodontal tissue making its degradation a hallmark of the uncontrolled
destruction in periodontitis46. Soft and hard tissue destruction is thought to reflect a
cascade of virulence factors and bacterial enzymes, pro-inflammatory cytokines,
chemokines and several apoptotic and immune responses47. Furthermore, the
dysregulation of the TIMPs, fails to provide the protective effect over the
overexpression of MMPs, hijacking the host defenses against inflammation48,49.

Membrane-bound Matrix Metalloproteinases

There was some controversy about the role of membrane-type MMPs (MTMMPs) in periodontal inflammation.

In recent years, several studies have shown

increased expression and activity of MMP-14 (MT1-MMP) in human and animal models
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of periodontitis, especially when stimulated by inflammatory cytokines such as TNFα48,50,51. More importantly, MMP-14 can activate proMMP-2 as a part of a ternary
complex formed by proMMP-2, MMP-14 and paradoxically, TIMP-2, adding one more
component for ECM degradation52. MMP-14 and MMP-2 can for a complex to activate
proMMP-1353,54

The Collagenases: MMP-1, MMP-8 and MMP-13

MMP-1 gene polymorphisms have been linked to increased susceptibility to
periodontitis, especially in Chinese patients55. Elevated levels of plasma MMP-8 and
MMP-9 correlate with high levels in GCF and saliva56–59. In recent years, there have
been new developments with stick-based tests to detect MMP-8 in the periodontal
pocket. This chair-side technique would allow clinicians to discern between gingivitis
and active periodontitis foci, permitting targeted therapy and possibly, better treatment
outcomes60–63.

Because

MMP-8

is

produced

during

degranulation

of

polymorphonuclear neutrophil PMN, presence of MMP-8 in gingival crevicular fluid
correlates with active inflammation and alveolar bone loss, and it has been shown to
decrease after periodontal therapy63,64. Because of the PMN activity, myeloperoxidase,
the enzyme that synthesizes hypochlorous acid in neutrophils, also correlates well with
MMP-8 and MMP-14 levels relating to active periodontitis. It is also a useful marker to
identify active sites and effectiveness of treatment48,65,66.
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The Gelatinases: MMP-2 and MMP-9

Both MMP-2 and MMP-9 has been shown to be expressed by gingival fibroblast
and gingival keratinocytes67. Although there is no chair-side testing available, they have
both been found in the GCF and correlated with sites of active periodontitis. MMP-14 is
co-localized with MMP-2, supporting the case for MMP-14 dependent activation50,68.
Polymorphisms in the MMP-9 gene (C-to-T at -1562) are linked to early-onset,
generalized aggressive periodontitis69–71.
A recent study used IL-1 β to induce an acute model of peritonitis in mice72.
Although different from periodontitis, this peritonitis model studies the role of MMPs
in chemoattraction and neutrophil recruitment. The study showed that MMP-2 and
MMP-9 were required to activate CXCL5, the chemokine that promoted neutrophil
migration into the peritoneal cavity. The study also showed that MMP-2 as produced
from resident cells and the MMP-9 was secreted from leukocytes. This study provides
an interesting model for periodontitis since both of these MMPs are present and CXLC5
is correlated to periodontitis severity, especially in smokers57,73. The pro-inflammatory
signals that activate MMP-2 and MMP-9 for neutrophil recruitment and activation of
chemokines could also be occurring in periodontitis and improper regulation of MMP-2
and MMP-9 might lead to ECM degradation.
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The Stromyelisins: MMP-3

MMP-3 has also been associated with tissue destruction in periodontitis,
especially in smokers. Levels of MMP-3 in GCF were significantly increased, positively
correlated with number of pack-years and a good predictor for attachment loss74.
Patients with a 5A/6A functional polymorphism in the -1612 of MMP-3 gene promoter
are also 3 times more likely to develop periodontitis than other genotypes, including
5A/5A75.

Conclusion

MMPs are an important contributor to ECM destruction in periodontitis.
Remarkably, MMPs are produced by the host and also cause damage to the host. The
role of bacterial infection is critical to triggering MMP expression but the bacteria alone
are not the cause of the ECM damage. The host loses its ability to regulate MMP
production and activity and this leads to ECM damage and alveolar bone loss. Once
formed, MMPs act in concert to degrade the ECM and basement membrane leading to
loss of attachment, alveolar bone destruction and tooth loss. This dissertation examines
molecules that stimulate inflammation and MMP production and also examines
inhibitors of MMP activation, even in the presence of inflammation as a potential
treatment to prevent ECM damage by MMPs.
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Chapter 3 Elevated homocysteine promotes matrix metalloproteinase production in a
chronic periodontitis model

Clinical Relevance

Scientific rationale Homocysteine is known to be elevated in the serum and
gingival crevicular fluid of patients with chronic periodontitis. Additionally,
periodontopathogenic bacteria can synthesize H2S from homocysteine, suggesting a link
between homocysteine levels, bacterial proliferation, and disease activity.

Principal findings Elevated homocysteine induces the expression of Matrix
Metalloproteinase-2 (MMP-2), MMP-3, MMP-9, MMP-13, and MMP-14. Use of an ERK
½ or an Akt inhibitor prevents the stimulatory effect of homocysteine.

Practical implications Control of homocysteine levels and its regulatory
molecules can ameliorate the production of matrix metalloproteinases and help
controlling extracellular matrix damage, halting disease progression.

Abstract
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Aim Homocysteine levels are elevated during chronic inflammatory conditions,
causing cell damage through different mechanisms, including the increase in matrix
metalloproteinase production. Chronic periodontitis is a chronic inflammatory
condition that presents increased homocysteine in plasma and in the gingival crevicular
fluid, yet its role is unclear. We aim to determine the effect of elevated homocysteine
levels by using a human gingival fibroblast inflammation model.

Materials and Methods Human Gingival Fibroblasts were induced with
lipopolysaccharide from P. gingivalis (5 µg/mL) or treated with homocysteine solution
(20 µM – 100 µM) and incubated for 48 hours. Protein and RNA samples were isolated
from the tissue cultures and media. Western Blot and qPCR for different matrix
metalloproteinases were performed. Possible mechanisms of activation were also
investigated through the use of signaling pathway inhibitors concurrently with
lipopolysaccharide and homocysteine.

Results Homocysteine was shown to increase levels of MMP-2, -3, -9, -13 and -14.
This effect is dependent on Akt and ERK ½ activation.

Conclusion Increase in homocysteine levels contributes to periodontal disease
through an increase in matrix metalloproteinases that promote tissue damage.
Targeting of Akt, ERK ½ and the matrix metalloproteinases activation pathway offer a
therapeutic target to reduce the effect of homocysteine and limit periodontium damage.
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Background

Homocysteine (Hcy) is a non-protein amino acid derived from the metabolism of
the essential amino acid methionine via methyl group metabolism. In recent years,
hyperhomocysteinemia has been linked to a range of high profile inflammatory
conditions, including cancer, autoimmune disorders, neurodegenerative diseases
vascular diseases and pregnancy complications1. In normal adults Hcy levels vary
according to vitamin levels, with a normal range of 6-15 µM. In inflammatory
conditions it is possible to find levels ranging from 20-500 µM2.

Deficiencies in

vitamin B6,

B12,

or

folate

are

major

contributors to

hyperhomocysteinemia3. During inflammation vitamins mobilize from the liver and
peripheral tissues to the sites of inflammation4 or are used to control inflammatory cell
activation and proliferation5. These alternative uses deplete the vitamin supply
available for transmethylation reactions necessary for the remethylation of Hcy into
methionine or trans-methylation into cystathionine. Therefore, an increase in Hcy levels
can be used as a biomarker for inflammatory processes6. A brief overview of Hcy
metabolism is described in Figure 3.17.
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Figure 3.1 Homocysteine metabolism. Homocysteine can be converted back to methionine through
remethylation with 5-methyl-tetrahydrofolate (5-methyl-THF), in a reaction catalyzed by vitamin B12dependent methionine synthase7. Methionine is activated by Adenosine triphosphate (ATP) to Sadenosylmethionine (SAM). SAM forms S-adenosylhomocysteine, releasing adenosine as a final step
before going back to Homocysteine8. In a minor pathway, homocysteine can gain a methyl group from
betaine to be converted into methionine. In the trans-sulfuration reaction homocysteine is converted into
cysteine. Two vitamin B6 – dependent enzymes facilitate this process: cystathionine ß-synthase (CBS) and
cystathionine γ- lyase (CGL). CBS catalyzes the condensation of homocysteine and serine to cystathionine
and CGL subsequently catalyzes the hydrolysis of cystathionine to cysteine and α-ketobutyrate. Excess
cysteine is oxidized to taurine or inorganic sulfates or is excreted in the urine.
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Mechanisms of homocysteine toxicity
Over the years, possible mechanisms for Hcy toxicity have been proposed. The
deleterious effects of homocysteine are summarized in Figure 3.2. In the following
section we will dwell briefly about these processes.

Figure 3.2 Mechanisms of homocysteine toxicity. Excess of homocysteine is detrimental to most organs.
The diversity in the toxicity mechanisms indicates a possibly role in many diseases ranging from
athrosclerosis to schizophrenia. Homocysteine-induced toxicity may overwhelm cellular defense
mechanisms and lead to cell death

Cytokine production

Homocysteine has been linked with chronic inflammatory conditions, and tend
to present itself along with other inflammatory markers, such as interleukin-1β (IL-1β),
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tumor necrosis factor (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-18
(IL-18) and C-reactive protein (CRP). Whether there is a causal relationship, or this is
increase is merely concomitant varies according to the condition9–12. Homocysteine has
been shown to induce the expression of Il-1 in synoviocytes, IL-6 in monocytes and IL-6
and IL-8 in endothelial cells13–15. Recent research suggests this could be mediated by
NFκ-B, as homocysteine can induce pro-inflammatory gene expression via Hcyrespondent transcription factors, including TNF-α signaling (including NFκ-B),
interferon-γ (IFN-γ) and other stress-signaling factors16.

Oxidative stress

Currently, it is believed that cells exposed to increased levels of homocysteine
undergo auto-oxidation of thiol groups, generating hydrogen peroxide and radical
oxygen species, such as superoxide and hydroxyl radical, ultimately resulting in
oxidative stress6

One well-documented effect of homocysteine-induced oxidative stress is the
reduction of the bioavailable Nitric oxide (NO). Hyperhomocysteinemia causes the
accumulation of asymmetric dimethyl arginine (ADMA), suppressing the activity of
endothelial NOS (eNOS) and inducible NOS (iNOS)17. Additionally, Hcy upregulates
the Protease-activated receptors (PAR-4 and PAR-2) upregulating NAPDH oxidase18,19
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and downregulating thioredoxin production, furthering the production of ROS and the
oxidative stress.

Homocysteine also attacks physiological defense mechanisms against oxidative
stress by downregulating Glutathione Peroxidase20,21 and through its effect in
glutathione (GSH) production. Synthesis of glutathione occurs in all cell types, with the
liver being the main producer and exporter of GSH. However, cysteine is the ratelimiting molecule in GSH production, and it can be affected when high levels of
homocysteine are present, incapable of following the trans-sulfuration pathway22. The
reduction on cytosolic GSH worsens the oxidative stress, as the cell cannot handle the
burden of the excess in ROS and can lead to apoptosis23.

Protein N-homocysteinylation

Homocysteine thiolactone (HTL), a cyclic thioester, is synthesized by an
aminoacyl-tRNA synthetase in editing or proofreading reactions that prevent
translational incorporation of homocysteine into proteins24,25. HTL specifically binds to
lysine

residues,

making

lysine-rich

proteins

particularly

prone

to

covalent

modification26,27. The rate of intracellular formation of HTL depends exclusively of the
availability of the precursor, homocysteine, and the concentration of Hcy in
hyperhomocysteinemic conditions28.
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Homocysteinylation can alter the fold and function of the proteins and make
them more vulnerable to further oxidation. It can also induce aggregation and amyloid
formation due to the exposure of hydrophobic patches that favor the formation of
aggregates29. Secondary to this, homocysteinylated enzymes, such as glyceraldehydo-3phosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH can slow their
activities by up to 40% when significant amounts of HTL are present (50-100 fold excess
of HTL per lysine)25. Interestingly, some homocysteinylated proteins do not undergo
any significant structural changes30. Cellular and plasmatic HTL exists mostly as protein
N-linked Hcy, specifically linked to hemoglobin and albumin, accounting for ~75% and
~22% respectively. It has been proposed that these two proteins act as reservoirs to
prevent further homocysteinylation of more sensitive proteins7,31,32.

Endoplasmic reticulum stress

The endoplasmic reticulum (ER) is the protein-folding powerhouse of the cell,
orchestrating the synthesis, transport and folding of up to 1/3 of the proteins in
eukaryotic cells. It also serves as a site of biosynthesis of steroids, cholesterol and other
lipids and as a regulator of cellular calcium homeostasis33. Discrepancies between the
demand and the capacities of the ER function lead to ER stress, presenting with
accumulation of misfolded or unfolded proteins. This disturbance activates the
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unfolded protein response (UPR), involving three transmembrane proteins that attempt
to restore the normal function of the ER: A type-I ER transmembrane protein kinase
(IRE-1), the activating transcription factor 6 (ATF-6) and the PKR-like ER kinase (PERK).
If the UPR is insufficient, the proteins are marked for ER-associated degradation
(ERAD) pathway via ubiquitin-proteasome system. If the protein burden is too large for
ERAD, protein aggregation occurs. These aggregates are so toxic that they are capable
of inducing conformational diseases, such as neurodegenerative disorders and diabetes
and finally, apoptosis34.

Hyperhomocysteinemia contributes to ER stress by disrupting disulfide bond
formation and causing misfolding of proteins passing through the ER35,36. At the same
time, Hcy increases the expression and synthesis of several proteins such as GRP78/BiP
and GADD153, Homocysteine-induced endoplasmic reticulum protein (Herp) and
tunicamycin-responsive protein (RTP). These proteins cause the activation of the UPR
proteins or, in case of GADD153, cellular death37–39.

Homocysteine disrupts calcium homeostasis, adding a source of stress for the
ER. Calcium influx may be increased via the NMDA channel, by inducing Ca2+
transients or by releasing Ca2+ from intracellular calcium stores39–42. This provides
another demand for the already exhausted ER worsening the deleterious effects of the
stress.

61

Matrix Metalloproteinase expression and activity

Matrix metalloproteinases (MMPs) are calcium-dependent zinc-containing
endopeptidases known as the culprit proteins for extracellular matrix (ECM)
degradation. All MMPs are synthesized as zymogens, and require further processing to
become proteolytically active. In addition to their canonical function in ECM
remodeling, metalloproteinase activity is now linked to the control of immune
responses43. The activation of MMP-14, a membrane-anchored MMP, is carried out by
proprotein convertase subtilisin/kexin 3 (PCSK3) and will subsequently process
proMMP-244. proMMP-13 is activated by concerted activity between MMP-14 and
MMP-2 or MMP-345. Matriptase, a serine protease has been involved in activation and
induction of proMMP-3 in osteoarthritis and gastric carcinoma46,47.

Hyperhomocysteinemia is strongly correlated to cardiovascular disease, and it is
in this condition that the relationship between Hcy and MMPs has been studied
most48,49. Extracellular matrix remodeling is of critical importance in the pathogenesis of
atherosclerosis, giving an important role to tissue-remodeling molecules such as MMPs.
Because of their collagenolytic properties, MMPs are key in the destruction and
remodeling of the vessel wall. Activation of MMP-2 through Hcy has previously been
characterized in an in vitro model50. In addition, MMP-9 has been extensively studied
for its role in extracellular matrix remodeling within vascular tissue and
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atherosclerosis51,52. ERK1/2 and Akt have been found to regulate the homocysteineinduced MMP-9 expression endothelial cells53,54.

Homocysteine and Periodontitis
The link between hyperhomocysteinemia and elevated MMP levels suggests that
illnesses presenting with extracellular matrix destruction are likely to be exacerbated
with increased Hcy levels. Periodontitis is one such disease, where a chronic illness is
identified by the destruction of the tissue surrounding the teeth.

Periodontitis has been recognized as a dysbiotic inflammatory disease with an
adverse impact on systemic health4. Patients with chronic periodontitis have elevated
plasma Hcy5 levels that significantly decrease after non-surgical periodontal
treatment57, suggesting a link between active periodontitis and Hcy. During the course
of the disease, the gingival sulcus deepens and accumulates an inflammatory fluid
called gingival crevicular fluid (GCF). There have been reports of elevated levels of Hcy
in the GCF as well as the saliva of patients with periodontal disease58. Furthermore, it is
known that periodontopathogenic bacteria are able to synthesize H2S from cysteine and
Hcy, with H2S being positively correlated to bacterial proliferation, disease activity, and
halitosis59,60. In addition to the pungent odor, H2S increases ROS leading to DNA
damage and eventual apoptosis in human gingival fibroblasts, furthering tissue
destruction recognized in periodontitis0.
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Tissue destruction in periodontitis is due to the presence of MMPs. Gingival
fibroblast, macrophages and neutrophils participate in the inflammatory process by
producing MMP and other cytokines in response to an initial bacterial insult and later
perpetuate the proinflammatory response.

In this study we establish a link between the hyperhomocysteinemia and the
elevation of several MMPs in a periodontitis model with human gingival fibroblasts
(HGF-1), along with a possible regulatory mechanism controlling this effect.

Materials and Methods

Cell Culture

Human gingival fibroblasts (HGF-1) were purchased from ATCC (Manassas,
VA) and were grown in DMEM with Glutamax, 10% FBS and Penicillin/Streptomycin
(Gibco) and kept at 37°C in a humidified air chamber with 5% CO2. HGF-1 cells were
seeded at 3x105 cells/flask for the experiments and then grown to 80% confluency, prior
to experimental incubation periods. Cell subcultures were between 3 and 10 passages
prior to use.
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Homocysteine solid (Sigma-Aldrich) was degassed and mixed with degassed
deionized water to obtain a 100 mM anaerobic stock solution. Homocysteine solutions
were prepared immediately prior to each experiment and used within 30 minutes of
degassing. Cells were induced with Hcy 15 µM – 100 µM, LPS and Chloromethylketone
(CMK) or a combination according to results figures, with cells permitted to continue
growth under incubation for 48 hours.

In the cell pathway assay, FR 180204 (ERK ½ inhibitor), Akt Inhibitor II,
Wortmannin (p38 inhibitor), a JNK inhibitor and a PI3K inhibitor were acquired from
R&D Systems and prepared according to manufacturer instructions. Cells were preinduced with the inhibitor for 1 hour prior to addition of Hcy 100 µM. Incubation at
37°C in a humidified air chamber with 5% CO2 continued for 24hrs prior to sample
collection.

Protein extraction

During protein extraction, media was collected, flash frozen and saved for
further analysis. Cells were washed with cold PBS and lysed with RIPA buffer (150 mM
NaCl, 50 mM Tris, 1% Sodium deoxycholate, 1% Triton X-100 and 0.1% SDS). Cells were
collected with a cell scraper and centrifuged at 14000 rpms for 30 minutes, with
supernatant collected and assayed for protein concentration. Samples were mixed with
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4X SDS Loading buffer (40% Glycerol, 8% SDS, 200 mM Tris-HCl, 400 mM
Dithiothreitol, 0.005% bromophenol blue) for further analysis.

Gel electrophoresis

12% Sodium dodecyl sulfate (SDS) - polyacrylamide gels were prepared by
standard methods. Equal amounts of protein were loaded in each lane (30-50 µg) and
allowed to separate for 1 hour at 150 V.

Western Blotting

Proteins from gels were transferred into 0.45 µm Nitrocellulose paper (Bio-Rad)
using Tris-Glycine transfer buffer with 20% Methanol using 400 mAmp for 90 minutes.
After transfer, membranes were removed from transfer boxes, rinsed in ddH2O, and left
to dry for 30 minutes. Nitrocellulose paper was blocked with Odyssey Blocking Buffer
(PBS) (LI-COR Biosciences) in a rocker at room temperature for 1 hour.

After blocking, 0.1% Tween-20 was added, along with the primary antibody.
Antibodies used were MMP-1 and MMP-3 (R&D Systems), MMP-2, -8, -9 (Cell
Signaling Technology, MMP-13 (Abcam), MMP-14 (EMD Millipore).
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Incubation was done according to manufacturer instructions for each antibody
prior to washing 3 times with TBS-tween. During secondary antibody incubation,
membranes were placed in dark boxes with a mix of 1:1 blocking buffer and PBS
containing 0.1% Tween-20 and the appropriate secondary antibody (LI-COR
Biosciences) for 60 minutes, at room temperature. Once the incubation was finalized,
blots were washed twice with TBS-tween and once with TBS. Membranes were stored
in TBS to prevent drying and scanned with a LI-COR Odyssey workstation for
densitometric analysis.

Images quantified using ImageStudio (LI-COR Biosciences) software.

RNA preparation from tissue culture, reverse transcription and RT2-qPCR

The tissue culture was washed with 1x PBS. Cells were lysed and RNA was
purified using RNeasy mini kits (Cat# 74104) from Qiagen according to manufacturer’s
protocol. All samples treated with Qiagen DNase (Cat# 79254). One microgram of RNA
was used for reverse transcription and subsequent SYBR® Green real time PCR for the
genes of interest. Reverse transcription kits (Cat #330401) and SYBR Green real-time
PCR master mixes (Cat# 330523) were acquired from Qiagen (Louisville, KY).

The following primers and probes were used:
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Human

MMP-2;

MMP2

(Cat#

PPH00151B),

Human

MMP-8;

MMP8

(Cat#PPH00908C), Human MMP-13; MMP13 (Cat# PPH00121B), Human MMP-14;
MMP14 (Cat# PPH00198C), and Human glyceraldehyde 3-phosphate dehydrogenase;
GAPDH (Cat# PPH00150F).

Real time quantitative PCR was performed on an Applied Biosciences StepOne
plus instrument and analyzed with StepOne software v2.3. The relative amounts of
transcripts from each gene were normalized to reference gene GAPDH and calculated
as follows: ∆∆CT = the average ∆CT of sample B – the average ∆CT of sample B, and their
fold difference = 2- ∆∆CT as previously described 62.

Results

Homocysteine induces the expression of proprotein convertase 3 (PCSK3) -activated
MMP-14 as well as MMP-14-activated MMP-2 and MMP-13

Based on previous work suggesting that Hcy was able to activate expression and
secretion of MMPs in endothelial cells during vascular disease, we tested the effect of
Hcy for inducing MMPs in human gingival fibroblasts cells (HGF-1). To activate the
expression of MMPs, HGF-1 cells were induced with physiologically normal Hcy
concentrations (15 µM) or elevated Hcy levels mimicking that observed in periodontitis
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(100 µM) 63. A positive control for inflammation was included by treating cells with LPS
from P. gingivalis, 5 µg/mL. The LPS concentration was within the working range of
previously used in periodontal models using HGF-1 culture64. Since some MMPs,
specifically proMMP-14, -15 and -16, are proteolytically activated by the proprotein
convertase PCSK3 during secretion from the cell, we used the known PCSK3 inhibitor
chloromethylketone (CMK) to halt its activity65. Additional studies were performed
using combinations of LPS 5 µg/mL, CMK 25 µM or the combinations of Hcy/LPS or
Hcy/CMK. Cells were incubated under these conditions for 48 h. Media and cell extract
samples were collected, and prepared for SDS-PAGE.

Figure 3.3 shows the effect of homocysteine on MMP-2, MMP-13 and MMP-14
production from HGF-1 cells. Reduced-serum media (Opti-MEM) from these cells was
collected and tested for proteolytically processed MMP-2 and MMP-13 and cell samples
were collected to establish expression of MMP-14. The results show that elevated levels
of Hcy (100 µM) cause a 2-fold increase in MMP-2 secretion (Figure 3.3A).
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Figure 3.3 Homocysteine increases the levels of MMP-2, MMP-13 and MMP-14. A. Blot analysis shows
a significant difference between the MMP-2 bands after 48 hr incubation with homocysteine 100 µM and 5
µg/mL LPS. The effect is synergistic when LPS and Hcy are combined. (p<0.001, ANOVA) (n=3) B.
Graphical representation of densitometry scans from three MMP-13 western blots in HGF-1 cells. A
significant difference is seen with Hcy and LPS induction (p< 0.05, ANOVA) and Hcy/LPS induction
(p<0.001, ANOVA) (n=3). C. Western blot analysis of MMP-14 shows a significant, synergistic increase in
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MMP-14 production after 48 hr incubation with homocysteine 100 µM and 5 µg/mL LPS (p<0.001,
ANOVA) (n=3). Error bars represent standard error.

Chloromethylketone was used to evaluate the effect of inhibiting PCSK3 while
concurrently inducing with Hcy. Cells incubated with both 100 µM Hcy and 25 µM
CMK reduced their MMP-2 secretion to basal levels. Other controls show that secretion
of MMP-2 after 100 µM Hcy exposure was similar to MMP-2 secretion with LPS
indicating that Hcy is and equally potent inducer of MMP production under these
conditions. Additionally, the combination of LPS and Hcy together did not
synergistically enhance MMP-2 secretion.

Figure 3.3B illustrates Hcy as upregulating MMP-13 within HGF-1 cells. LPS did
not upregulate MMP-13 to the same extent as Hcy. CMK inhibits MMP-13 expression
during exposure to both CMK and 100 µM Hcy.

Figure 3.3C illustrates Hcy-induced MMP-14 production in HGF-1 cells similar to
that of MMP-2 and MMP-13. Additionally, LPS induces MMP-14 and the combination
of both Hcy and LPS synergistically enhances MMP-14 production. MMP-14 is cleaved
and activated by PCSK3. Here, CMK is used to inhibit PCSK3 activity, and thereby
limits the presence of mature MMP-14 despite the presence of 100 µM Hcy. The
decrease in MMP-14 is consistent with the decrease in MMP-2 and MMP-13.
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Homocysteine induces the expression of MMP-3 and MMP-9

Figure 3.4 displays the effect of homocysteine in MMP-3 and MMP-9 production
in HGF-1 cells. Figure 3.4A illustrates elevated levels of Hcy (100 µM) cause
approximately 2-fold increase in MMP-3 production. The production of MMP-3 when
HGF-1 cells were treated with both 100 µM Hcy and 25 µM CMK decreased to the same
level as healthy cells indicating that CMK inhibited MMP-3 production in the presence
of Hcy. Other controls show that secretion of MMP-3 after 100 µM Hcy exposure was
more extensive than with LPS alone. These results are similar but not identical to those
observed for MMP-2.

Figure 3.4B demonstrates that treatment of HGF-1 cells with 100 µM Hcy causes
elevation in MMP-9 production. LPS also activates MMP-9 production. However, in
comparison to MMP-2 and MMP-3, MMP-9 is activated to a lesser extent, 1.5 fold
instead of 2-fold. CMK did not inhibit MMP-9 production from HGF-1 cells.
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Figure 3.4 MMP-3 and MMP-9 expression is induced by homocysteine. A. Western blot analysis shows
a significant difference between the MMP-3 bands after 48 hr incubation with homocysteine 100 µM and 5
µg/mL LPS. The effect is synergistic when LPS and Hcy are combined. (p<0.01, ANOVA) (n=3) B.
Graphical representation of densitometry scans from three MMP-9 under previously described
conditions. The presence of CMK does not alter MMP production when induced with Hcy. A significant
difference is seen with Hcy and LPS induction (p< 0.001) and Hcy/LPS induction (p<0.01, ANOVA)
(n=3). Error bars represent standard error.

Homocysteine does not affect production of MMP-1 or MMP-8

In addition to the previously mentioned MMPs, we tested cell and media
samples for MMP-1 and MMP-8. It is clear that MMP-1 expression levels do not change
under inflammatory conditions induced by LPS or Hcy in HGF-1. In addition, MMP-1
expression is not decreased by CMK (Figure 3.5A).
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Figure 3.5 MMP-1 and MMP-8 expression is not affected by homocysteine. A. Western blot analysis
shows no significant difference between the MMP-1 bands after 48 hr incubation with homocysteine 100
µM and 5 µg/mL LPS. (p>0.05, ns, ANOVA) (n=3) B. Graphical representation of densitometry scans
from three MMP-8 under previously described conditions. The presence of homocysteine or CMK does
not alter MMP production. (p>0.05, ns, ANOVA) (n=3) Error bars represent standard error.

We also tested HGF-1 cells to determine if MMP-8 is produced by HGF-1 cells in
response to inflammation as a second source of MMP-8 production. The results shown
in Figure 3.5B indicate that neither Hcy nor LPS nor the combination of the two induced
additional expression of MMP-8 from HGF-1 cells. In addition, CMK did not inhibit the
secretion of MMP-8 from HGF -1 cells. These results are important for understanding
the damage caused in periodontitis because they implicate neutrophils as the source of
MMP-8.
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Effects of Homocysteine on MMP gene expression

Figure 3.6 is a summary of the qPCR analysis for each MMP. This is important
because it shows the stimulation of mRNA by Hcy. In contrast, the western blot analysis
described above shows the actual production of the activated protein. Differences in the
qPCR results and the western blot analysis indicate that the mRNA was made and
potentially the precursor proMMP protein but if the proMMP was not activated by
either PCSK3 or MMP-14, the protein might have been degraded.

Figure 3.6 mRNA expression of MMPs after treatment with homocysteine. Graph shows expression of 5
different MMP genes after homocysteine induction (100 µM). Combined induction with homocysteine
and CMK is no different from homocysteine induction alone. (p<0.001, ANOVA) (n=3)
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The qPCR shows that 100 µM Hcy acts as an inducer of gene expression of the
MMPs in HGF-1 cells except for MMP-8. The qPCR in HGF-1 cells treated with 100 µM
Hcy shows expression of the MMP-2, MMP-3 and MMP-14 genes to make mRNA but
the western blot analysis shows that treatment with CMK prevents an increase over
healthy levels of the formation of the active forms of these MMPs. This suggests that
inhibition of PCSK3 prevents the production of active MMPs even when the genes are
activated and transcribed.

HGF-1 cells incubated with Homocysteine exhibited significant increase in
MMP-2, MMP-9, MMP-13 and MMP-14 expression
.
Homocysteine effect on MMP expression is mediated by Akt and ERK ½

We chose to evaluate MMP-2 as the final product in our studies of the Akt and
Erk ½ pathway studies because MMP-2 plays a role in periodontitis and participates in
the cleavage of other pro-MMPs and cytokines. We evaluated 5 different intermediates,
namely Akt, ERK1/2, JNK, p38, PI3K, using western blot analysis.
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Figure 3.7 Homocysteine induces MMP through Akt and ERK ½. A. Western blots and graphical
representation of homocysteine inducing MMP-2 secretion into reduced serum media with and without
an Akt inhibitor. Phosphorylation site for Akt is Ser473. Values were normalized with histone H3. (p<
0.01, ANOVA, n=4). B. Western blots and graphical representation of homocysteine inducing MMP-2
secretion into reduced serum media with and without an ERK ½ inhibitor (FR 180204). Doublet
represents fragments p42 and p44 of ERK ½. Phosphorylation sites for ERK ½ are Thr202/Tyr204. Values
were normalized with histone H3. (p< 0.01, ANOVA, n=4).

The role of Akt was evaluated by pre-treating the cells with Akt Inhibitor II (10
µM) followed by inducing HGF-1 cells with 100 µM Hcy. Figure 3.7A shows the results
the pre-incubation of Akt Inhibitor II (10 µM Akt) with HGF-1 cells followed by
treatment of the cells with treatment 100 µM Hcy for 24 hours. Proteolytically processed
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MMP-2 increases with Hcy treatment but the pre-incubation with Akt Inhibitor II
resulted in normal MMP-2 levels.
The role of Erk ½ was evaluated by pre-treating the cells with FR180204
(selective ERK 1 and ERK 2 inhibitor, 10 µM), followed by inducing HGF-1 cells with
100 µM Hcy. Figure 6B shows that elevated Hcy levels increased MMP-2 production but
the use of FR180204 brought the MMP-2 production back to normal levels (Figure 3.7B).
Phosphorylated ERK ½ (pERK) was increased with Hcy treatment and was effectively
inhibited by FR180204.

In both cases, Hcy increased the MMP-2 expression by 1.5 times. The higher
increase seen on previous experiments is due to a shorter incubation period done to
preserve the phosphorylation of the involved molecules (compare the ~2-fold increase
of MMP-2 in Figure 3.3A to the ~1.5-fold increase of MMP-2 in Figure 3.7A).

Preinduction with PI3K, JNK and p38 inhibitors did not show a decrease in
MMP-2 production, despite effectively inhibiting the phosphorylation of the
intermediate molecules. When combined, this data suggests that Hcy activated Akt and
ERK ½ pathways to induce MMP-2 expression.

Discussion
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We demonstrate that treatment of HGF-1 with pathologically elevated levels of
Hcy increase the production of MMP-2, -3, -9, -13, -14. This effect is mediated by Akt
and ERK ½. Additionally, concurrent treatment with the PCSK3 inhibitor
chloromethylketone prevents the activation of proMMP-14 and subsequently, MMP-2
and MMP-13.
MMP-14 is a membrane bound MMP heavily involved in tissue destruction in
periodontitis thanks to collagen I degradation66,67. MMP-14 functions to activate
secreted MMPs by cleaving the prodomain of proMMP-2 and proMMP-13 to make
them active. MMP-2 and MMP-13 are also involved in periodontitis correlating strongly
with periodontal lesion progression and alveolar bone loss68,69. Control of PCSK3
activity offers as a potential therapeutic target for preventing the activation of MMP-14
and its pro-MMP substrates.

CMK is a known inhibitor of Matriptase, explaining the inhibition of MMP-3
displayed in figure 3.4A. Alternatively, the inhibition of MMP-3 with CMK suggests
another, as yet identified step that involves MMP-14, as MMP-3 does not contain a
PCSK3 recognition site.

MMP-9 is heavily involved in periodontitis, and some polymorphisms are
associated with aggressive forms70. While Hcy was capable of increasing MMP-9
production, CMK did not alter Hcy-induced MMP-9 secretion. This is easily explained
because pro-MMP-9 does not include a PCSK3 cleavage site and therefore is not directly
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cleaved by PCSK3. In vitro studies have suggested that pro-MMP-9 could be activated
by several pathways, including the coordinated activity of MMP-3, MMP-2 and MMP14.

Other

studies

have

also

suggested

the

involvement

of

plasminogen

activator/plasmin (PA/plasmin), activated protein C (APC) or a highly regulated serine
protease cascade71–74. Selectivity in treatments could be an important method for
controlling the damage caused by MMPs while allowing the activity of MMPs that
perform other essential functions.
This study demonstrates that high levels of Hcy elicit the production of MMPs in
human gingival fibroblasts. Control of regulatory molecules Akt and ERK ½ as well as
PCSK3 can prevent the damaging effect of Hcy. Additionally, control of Hcy levels
through vitamin B supplementation could limit the amount of damage in the
periodontium by reducing the expression of MMPs.
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Chapter 4. Citrate and Albumin Facilitate Transferrin Iron Loading in the Presence of
Phosphate and Prevent the Formation of Non-Transferrin Bound Iron

Abstract

Labile plasma iron (LPI) is redox active, exchangeable iron that catalyzes the
formation of reactive oxygen species.

Serum transferrin binds iron in a non-

exchangeable form and delivers iron to cells. In several inflammatory diseases serum
LPI increases but the reason LPI forms is unknown. This work evaluates possible
pathways leading to LPI and examines potential mediators of apo transferrin iron
loading to prevent LPI. Previously phosphate was shown to inhibit iron loading into
apo transferrin by competitively binding free Fe3+. The reaction of Fe3+ with phosphate
produced a soluble ferric phosphate complex. In this study we evaluate iron loading
into transferrin under physiologically relevant phosphate conditions to evaluate the
roles of citrate and albumin in mediating iron delivery into apo transferrin. We report
that preformed Fe3+-citrate was loaded into apo transferrin and was not inhibited by
phosphate. A competition study evaluated reactions when Fe3+ was added to a solution
with citrate, phosphate and apo transferrin. The results showed citrate marginally
improved the delivery of Fe3+ to apo transferrin. Studies adding Fe3+ to a solution with
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phosphate, albumin and apo transferrin showed that albumin improved Fe3+ loading
into apo transferrin. The most efficient Fe3+ loading into apo transferrin in a phosphate
solution occurred when both citrate and albumin were present at physiological
concentrations. Citrate and albumin overcame phosphate inhibition and loaded apo
transferrin equal to the control of Fe3+ added to apo transferrin. Our results suggest a
physiologically important role for albumin and citrate for apo transferrin iron loading.

Introduction

Chronic inflammatory diseases such as diabetes and kidney disease are often
accompanied by oxidative stress1,2. Oxidative stress occurs when reactive oxygen
species (ROS) damage biological molecules and this damage leads to further
complications such as atherosclerosis and heart disease3. In fact, cardiovascular and
cardiopulmonary complications are listed as the number one cause of death of diabetes
and chronic kidney disease patients4,5. The iron-binding serum protein transferrin binds
tightly to iron in plasma to sequester it in a non-exchangeable, redox inactive form that
keeps free iron levels low in the bloodstream to prevent the formation of ROS6

Oxidative stress caused by free iron was originally observed in patients with iron
overload diseases such as hemochromatosis or thalassemia7. Free iron occurred because
the total iron binding capacity of transferrin had been exceeded and transferrin could
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not accommodate the excess iron8. This labile iron became known by the generic term,
non-transferrin bound iron (LPI). However, the term LPI includes iron that exists as
low molecular mass complexes of iron that form in excess of the total binding capacity
of transferrin but also includes iron in ferritin, heme and iron bound advantageously to
other proteins and biological molecules6.

Not all LPI is redox active or readily

exchangeable nor does all LPI act as a catalyst for ROS. The term labile plasma iron
(LPI) provides a more specific definition of redox active, exchangeable iron found in the
bloodstream that acts as a catalyst for oxidative stress but is not bound by transferrin.
In this manuscript, we will use the term LPI to designate redox active, exchangeable
iron that does not bind to apo transferrin6.

In recent years, LPI has been found in inflammatory conditions where plasma
iron levels were low and transferrin was not saturated. For example, LPI was observed
in patients with end stage renal disease, kidney disease, diabetes and cancer, all
conditions with unsaturated transferrin8–12.

The presence of LPI in patients with

unsaturated transferrin is puzzling considering that Tf has such high affinity for
binding iron. In vitro, Tf easily binds monomeric Fe(III) in carbonate buffer with an
estimated binding constants between 1017 to 1022 13.

Past studies on LPI suggest that some LPI species exists as small complexes with
organic acid ligands such as Fe(III)-citrate and some LPI complexes are larger because
they are retained by 30 kDa membrane filters14,15. The larger complexes have not been
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characterized but are proposed to represent polymeric Fe(III) species or protein bound
Fe(III), most likely complexed to albumin14. In fact, glycated and oxidized albumin,
which forms under conditions present in diabetes and kidney disease, was able to bind
iron more tightly than normal albumin1,16.
Several models could explain the presence of LPI when transferrin is not
saturated with iron and include: 1) oxidative damage to apo transferrin that prevents
iron loading, or 2) inflammation causing the formation of iron complexes that are not
bio-available to apo transferrin.
Oxidative stress is prevalent with inflammation and many studies have been
performed to determine the effect of oxidative stress on serum proteins. Albumin has a
redox active cysteine residue that is rapidly oxidized by oxidative stress and the high
abundance of albumin in serum and its redox ability allows albumin to be the major
redox buffer in serum17,18. Himmelfarb et al. reported that albumin oxidation occurred
preferentially, sparing other serum proteins, including transferrin, from oxidation17.

The second model, suggesting iron is packaged into a biologically inaccessible
complex that is unavailable for binding to transferrin is a reasonable and indirectly
supported hypothesis.

Renal patients on dialysis suffer from oxidative stress and

anemia and both conditions are exacerbated by the dialysis procedure. These patients
are treated with iron supplements and erythropoietin to stimulate red blood cell
synthesis19. Unfortunately, many of the intravenous iron supplements are polymeric
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and studies have shown that polymeric iron species are poor substrates for loading into
transferrin20.

The Fe(III) from these supplements follows a complicated pathway to enter the
biological iron pool. The polymeric iron supplements are typically absorbed by the
reticuloendothelial system that includes macrophages and liver cells20. The polymeric
iron complexes are broken down inside cells to form monomeric Fe2+ and the cytosolic
Fe2+ can then be exported back into the bloodstream from these cells through
ferroportin. As Fe(II) exits the cell through ferroportin, it is oxidized by the copper
oxidase enzyme ceruloplasmin resulting in the released of Fe(III) into the serum21.
Under healthy condition Fe(III) quickly binds to Tf and is subsequently transported and
delivered to cells that require iron through receptor mediated endocytosis of transferrin
receptors. During inflammation, the iron exporting system that redistributes iron back
into serum and ultimately to the bone marrow for red blood cell synthesis is shut down
because the iron hormone hepcidin binds to ferroportin and degrades this iron
exporter22.
A potential window when LPI might be produced occurs when Fe2+ is exported
through ferroportin. Under normal conditions Fe2+ is transferred through ferroportin
and out of the cell where it is oxidized by ceruloplasmin and momentarily exists as
“free Fe3+”. The biological target for this “free Fe3+” is to bind to apo transferrin.
However, “free Fe3+” is able to react with other serum molecules to form complexes or
precipitate. An additional complication during inflammation is that several molecules
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known to react with “free Fe3+ such as inorganic phosphate (Pi), citrate and hydroxide
are found at altered concentrations in chronic inflammatory diseases. In fact, Hilton
demonstrated that soluble ferric phosphate complexes form when iron is added to a
phosphate solution23. This study evaluates reactions involving hydroxide, Pi and citrate
and we propose that these altered metabolite concentrations disrupt iron binding by
transferrin (Summarized in Scheme. 1). We use an in vitro model to test the hypothesis
that alterations in the concentration of these serum molecules tips the balance from
normal transferrin iron loading to LPI formation.
In this study we begin to evaluate the hypothesis that inflammation alters the
complicated matrix of molecules present in serum and disrupts normal iron chemistry
leading to the formation of polymeric iron species that are not recognized by apo
transferrin.
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Scheme 4.1 Potential reactions of Fe3+ in the bloodstream after export through ferroportin. After export
through ferroportin (FPN) monomeric Fe3+ can react with many serum components such as hydroxide
ion (OH–), inorganic phosphate (Pi), transferrin (Tf), and citrate (the healthy concentrations of each
component is shown). Our hypothesis is that citrate quickly complexes Fe3+ as it exits ferroportin and
stabilizes Fe3+ so it does not react with OH- or phosphate but is loaded into apo transferrin (green
pathway). In fact, control reactions with pre-formed Fe-citrate rapidly load Fe3+ into apo transferrin and
are not inhibited by phosphate (red). The critical experiment is to test iron loading into apo transferrin
with a competition reaction where both citrate and phosphate are present in solution and Fe3+ is added as
if exported from ferroportin to see if citrate is able to overcome the phosphate inhibition and still load
iron into apo transferrin (purple arrows). These experimental conditions are tested in this work
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Materials and Methods

Materials
Human apo-transferrin was purchased from Lee Biosolutions (Maryland
Heights, MO) Prior to iron loading, apo-transferrin (78 kDa) was prepared in a solution
of 25 mM MOPS (3-(N-morpholino)propanesulfonic acid), pH 7.4. Bovine serum
albumin was purchased from Sigma and prepared in water. Fe(NH4)2(SO4)2∙H2O (Fe2+),
FeCl3 (Fe3+), Na2HPO4, Na3C6H5O7 , (Fe)C6H5O7 and NaHCO3, were all purchased from
Fisher. Fe2+ and Fe3+ solutions were prepared by dissolving the appropriate solid into
0.001 M HCl. Nitrilotriacetic acid (NTA) was purchased from Sigma. The pre-formed
Fe-citrate complex used in this study was prepared by placing the required amount of
ferric citrate solid into water to prepare a 10 mM solution and then autoclaving the
solution for 15 min to dissolve the ferric citrate solid. An iron analysis using the
bipyridine method was performed to accurately determine the iron concentration in the
solution23. The Fe-NTA complex was prepared as previously described24,25 by adding
FeCl3 to an NTA solution so that a 1:4 ratio of Fe3+ to NTA was achieved. The solution
was adjusted to pH 7.4 for the reactions.

UV/Vis Spectrophotometry. An Agilent 8453 UV/Vis spectrophotometer was
used to monitor the binding of iron to transferrin. Final concentrations of protein and
solutions were: 2.5 mg/mL transferrin (~ 3.2 x 10-5 M), in 25 mM MOPS buffer pH 7.4,
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10 mM CO32−, Pi concentrations as indicated in the figures, and either 64 µM (To
guarantee exactly 2 Fe/Tf, and prevent possible iron overload that would mask the pi
effect) Fe3+ or Fe2+. The kinetic runs were setup to monitor the change in absorbance at
460 nm versus time. Transferrin was incubated with carbonate in the absence or
presence of Pi and allowed to stir to equilibrate. The kinetic run was initiated by adding
the appropriate volume of Fe3+ or Fe2+. Runs were collected in triplicate and error bars
are shown, representing the standard error. Some reactions were initiated by adding
FeCl3 while other reactions were initiated by the addition of Fe3+-NTA or Fe-citrate.

Results

As Fe2+ is exported through ferroportin and is oxidized by ceruloplasmin, it will
exist transiently in solution as “free Fe3+” where it will react with other molecules in the
serum. The studies outlined in this work evaluate how rapidly and effectively, Fe3+ can
be bound by apo-transferrin in the presence of physiologically relevant molecules that
react with the transient “free Fe3+” ion.
The first test evaluated the effect of hydroxide ions, or pH, on Tf iron loading
under the defined assay conditions. Iron loading was conducted at pH 6.0, 7.0 and 8.0.
As the pH increased, we anticipated that the elevation in hydroxide ion concentration
would lead to more Fe(OH)3 formation and less Fe3+ would be available in solution to
load into transferrin. In contrast, as the pH was lowered towards pH 6.0, we anticipated
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that Fe3+ would remain more soluble and more Tf iron loading would occur. The data
shown in Figure 1 correlate exactly with these predictions with increased Fe3+ -loading
more rapidly into transferrin at pH 6.0 and iron loading into transferrin was decreased
at pH 8.0 as the Fe(OH)3 solid was observed.

Figure 4.1 Fe3+ loading into Transferrin as a function of pH. Fe3+ was added to a solution of apo
transferrin in 10 mM carbonate in MOPS buffer at pH 6.0 (yellow), pH 7.0 (blue) or pH 8.0 (green) and the
Tf Fe3+ and the iron loading reactions were monitored at 460 nm with time. As expected, Fe3+ loading into
transferrin was faster at pH 6.0 and inhibited at pH 8.0 due to the formation of Fe(OH)3 at higher pH.

Hilton et al. previously reported that Pi inhibited Fe3+ loading into transferrin.
However, the presence of iron-complexing molecules, such as NTA or citrate was able
to overcome the Pi effect26. In this study we examined the role of pre-formed Fe3+-citrate
to determine if a fully coordinated Fe3+ species would be protected against precipitation
of Fe3+ by Pi. Figure 4.2 shows the rate of the Fe3+ ion control reaction (yellow) loading
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into apo transferrin and the inhibition caused by normal Pi levels of 1 mM Pi (blue) and
the 10 mM elevated Pi reaction (green).

Figure 4.2 Complexed Fe3+ is not inhibited by phosphate. Fe3+ was added to apo Tf with no phosphate
(yellow) or in the presence of 1 mM phosphate (blue) or 10 mM phosphate (green). Iron was also added
to apo transferrin as a pre-formed complex of Fe3+-citrate in the absence of phosphate (red) or in the
presence of 1 mM phosphate (black). The results show that when Fe3+ is added without complexation it
loads into apo transferrin slower than when it is complexed and that phosphate can inhibit iron loading
into apo transferrin if the Fe3+ is not protected from phosphate by complexation.

When the Fe3+ ion is coordinated by a citrate prior to Pi exposure, transferrin
loads rapidly, even much faster than the Fe3+ ion control (red). Chelation of Fe3+ by
citrate (black) was not inhibited by 1 mM Pi and had the same iron loading kinetics as
the Fe3+ -citrate control that was not exposed to Pi. These results indicate that a fully
coordinated Fe3+ ion is a very good substrate for loading into apo transferrin and that
coordination protects Fe3+ from precipitation by Pi. This observation may be critical for
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the physiological pathway of transferrin iron loading in vivo in order to prevent the
formation of LPI.
The ability of citrate to complex Fe3+ and protect Fe3+ from precipitation by Pi
facilitates apo transferrin iron loading under physiological Pi levels and suggests that
citrate complexation of iron is an important step in prevention of LPI formation.
Additional evidence that citrate might play an important role in transferrin iron loading
by this model is given by the fact that serum citrate levels drop with inflammation.
Normal serum citrate levels are approximately 100 µM27. The lower citrate levels are
consistent with LPI formation with inflammatory diseases28 [23]. In contrast, citrate
levels increase with exercise and oxidative stress is known to decrease with exercise29.
Taken together, conditions with elevated citrate have less oxidative damage and
conditions with lower citrate have elevated oxidative stress and LPI.

Based on the model shown in Scheme 4.1, Fe3+ is exported through ferroportin as
an ion and enters the bloodstream, where it will encounter both citrate (100 µM) and Pi
(1000 µM). Under healthy conditions the Pi will be present at ~10-fold excess compared
to citrate. With inflammation, citrate levels will drop and Pi levels will rise. Figure 4.3
shows Tf iron-loading assays performed with both citrate and Pi present in solution.
This is to simulate molecules present when Fe3+ is exported through ferroportin in order
to evaluate how effectively citrate could compete with Pi for Fe3+ ion as it entered the
bloodstream. Experiments represent healthy levels of Pi (1 mM) with concentrations of
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citrate that represent inflammation (30 µM citrate), normal citrate (100 µM) and citrate
concentrations present after exercise (150 µM citrate) (Fig. 4.3).

Figure 4.3 Competition of 1 mM phosphate and citrate for Fe3+ in an apo transferrin iron-loading assay.
Fe3+ ions were added to apo transferrin solutions containing (orange) no phosphate or citrate, (green) 1
mM Pi, (red) 1 mM Pi, 30 µM citrate, (blue) 1 mM Pi and 100 µM citrate, or 1 mM Pi and 150 µM citrate
(purple). The presence of 100 µM or 150 µM citrate is unable to completely restore Tf iron loading to the
same level of Fe3+ ions alone but significantly improves iron loading compared to reactions without
citrate.

We also studied transferrin loading under end-stage renal disease (ESRD)-like
conditions where Pi is 10-fold higher than normal (10 mM Pi) to evaluate the ability of
citrate to overcome the precipitation of Fe3+ by Pi at 30 µM citrate and 100 µM citrate
(Supplemental Figure 4.1).

103

The lower final absorbance in each iron loading assay represents a lower
concentration of diferric transferrin forming based on the extinction coefficient of two
Fe3+ bound to apo transferrin30,31. An alternative method of studying the iron loading
state of transferrin is to use native urea gels. The loading of either the N-lobe or the Clobe of transferrin to make a monoferric transferrin species is known and can be
observed using this native gel technique32. A native urea gel of samples run identically
to the conditions of Figure 4.3 is shown in Figure 4.4. This gel shows that citrate aids in
iron loading, Pi inhibits iron loading but citrate present in solution with Pi helps
overcome the Pi inhibition to load transferrin.

Figure 4.4 Urea gel comparing the effectiveness of transferrin Fe3+-loading with different citrate
concentrations. Each iron loading reaction was added to sample buffer immediately at the endpoint of
the kinetic run. Lane 1 apo transferrin, Lane 2 diferric transferrin, Lane 3 Fe3+ loaded transferrin, Lane 4
Lane 3 Fe3+ loaded transferrin in 100 µM citrate, Lane 5 Fe3+ loaded transferrin in 1 mM Pi, Lane 6 Fe3+
loaded transferrin in 10 mM Pi, Lane 7 Fe3+ loaded transferrin in 10 mM Pi with 30 µM citrate, Lane 8 Fe3+
loaded transferrin in 10 mM Pi with 100 µM citrate.
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Our laboratory demonstrated that soluble iron-phosphate complexes form
during iron loading reactions with ferritin23. We speculated that the decreased
transferrin iron loading might be due to the formation of soluble iron-phosphate
complexes due to the lack of precipitation observed in the reactions. We tested for
soluble iron-phosphate complex formation during transferrin iron loading reactions by
depositing a small sample of the transferrin iron loading reaction onto a TEM grid and
performed TEM analysis on the samples. Figure 4.5A shows that Fe3+ added to an apo
transferrin solution containing 10 mM Pi produced spherical nanoparticles of
approximately 10 nm diameter size, consistent with our previous results that Fe-Pi
complexes formed under these conditions. Remarkably, when Fe3+ was added to a 10
mM Pi solution with 100 µM citrate present (Figure 4.5B), the Fe-Pi nanoparticles were
not observable. This study indicates that in the presence of citrate the amount of Fe-Pi
precipitation occurred at a much lower level, presumably because the iron was loaded
into apo transferrin. Elemental analysis by EDX showed the nanoparticles in panel 5A
were composed of iron and phosphorus, consistent with the formation of the proposed
Fe-Pi complex (Supplemental Figures 4.3A and 4.3B).

105

Figure 4.5 TEM analysis to visualize Fe-Pi complexes that form during transferrin iron loading in the
presence of phosphate and the role of citrate in preventing Fe-Pi complex formation. Analysis was
performed on a TF-20 Transmission Electron Microscope. A. Shows the TEM analysis of an iron loading
reaction performed by adding 2 Fe3+/Tf to a solution containing apo transferrin (32 µM) and 10 mM Pi.
Fe-Pi nanoparticles were imaged at 200KV, 0.2 µm resolution. Particles measured ~10-12 nm. B. The
identical reaction conditions used in A except the solution contained 100 µM citrate. In panel B, no Fe-Pi
nanoparticles were observed.

Up to this point in our study, the results show that as Fe3+ exits ferroportin, the
presence of citrate is important to mediate iron delivery to apo transferrin in the
presence of physiological 1 mM Pi concentrations. However, citrate does not completely
overcome Pi inhibition and LPI is still produced (Fig 4.3). Transferrin iron loading with
citrate is not maximal unless the Fe-citrate complex forms prior to exposure to Pi (Fig.
4.2). To further identify contributing factors to prevent LPI formation, we considered
the role of the serum protein albumin as an iron chelating protein and mediator of Fe3+
to transferrin. Human serum albumin is known to possess metal binding sites that
recognize and bind iron33,34.
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Albumin is a highly concentrated protein in the serum that assists with controlling the
osmotic pressure in the blood stream. However, many studies have shown a role for
albumin as a metal binding protein16,34,35.Albumin is found at normal concentrations
between 30-45 g/L (440-660 mM).

Hypoabluminemia occurs with inflammation

because albumin is a negative acute-phase protein and albumin is considered to be low
if it is below 30 g/L

18,36.

The research question we wish to address at this point in this

work is if albumin can act as an intermediate iron-binding molecule and facilitate Fe3+
loading into transferrin in the presence of Pi.

Silva confirmed the effectiveness of albumin binding Fe3+ and citrate.

Additionally

Silva studied oxidized and glycated albumin because these modifications to albumin
occur in diabetes and other oxidative stress diseases. Oxidized and glycated albumin
were shown to bind Fe3+ with much higher affinity than native albumin16. Ueno et al.
further showed that the combination of serum albumin in a carbonate buffer system
bound up to a 100-fold molar excess of iron and prevented lipid peroxidation reactions.
Based on these studies, we proposed that the high concentrations of albumin in serum
might rapidly bind “free Fe3+” released into serum by ferroportin and ceruloplasmin
and act to protect “free Fe3+” from reacting with serum molecules.
We also recognize that if Fe2+ were exported through ferroportin in the absence of
ceruloplasmin that “free Fe2+” would quickly encounter citrate and phosphate in serum.
In the presence of oxygen, citrate and phosphate rapidly catalyze the oxidation of Fe2+
to Fe3+37,38. In fact, our lab showed that Fe2+ is rapidly oxidized in the presence of
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phosphate and loads efficiently into apo transferrin and somehow bypasses the
formation of the ferric phosphate complex26. Early studies on ferroportin indicated a
ferroxidase enzyme such as ceruloplasmin or hephaestin were required for iron
release39–41, but more recent studies showed that oxo-anions such as citrate and
phosphate could mediate Fe2+ oxidation and allow for iron release from ferroportin41,42.
However, these conditions were not examined in this work.
The ability of albumin to bind both citrate and Fe3+ might allow albumin to protect the
iron from phosphate and help to mediate the Fe3+ to apo-transferrin.

Potentially

albumin might act as a “chaperone protein” to assist Fe3+ to form a complex with citrate
to further protect against precipitation by phosphate or hydroxide. Scheme 4.2 shows
how these protective reactions might occur. The remaining experiments in this work
examine this model with albumin and citrate as mediators of Fe3+ to load into apotransferrin.
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Scheme 4.2 Role of albumin and citrate in mediating Tf iron loading. We propose that the high
concentration of albumin in serum and the metal binding site in albumin allows Fe3+ to be rapidly
sequestered and protected from phosphate. The ability of albumin to mediate Tf iron loading alone
(orange) or to facilitate the formation of the Fe-citrate complex (blue) will be examined.

Figure

0.6
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Transferrin iron loading in the presence of albumin and citrate. Fe3+ was added to an apo transferrin
solution with: (orange) no other molecules, (green) 1 mM Pi, (pink) 1 mM Pi and 2 g/dL albumin, (blue) 1
mM Pi with 5 g/dL albumin, (purple) 1 mM Pi with 5 g/dL albumin and 100 µM citrate).

Figure 4.6 shows the results of Fe3+-loading experiments into apo transferrin
performed in the presence of 1 mM Pi and varying concentrations of albumin and
citrate. The results are shown in comparison to the Fe3+ control added to apo transferrin
without any other serum molecules present. Low albumin levels (2 g/dL) are
insufficient to overcome the 1 mM Pi inhibitory effect but normal albumin levels (5
g/dL) are able to increase transferrin iron loading levels to the same level as the control,
or in other words are able to block the Pi inhibitory effect. When healthy physiological
citrate levels (100 µM), are added with physiological levels of albumin (5 g/dL), iron
loading into apo transferrin is slightly better than the control of Fe3+ added without any
other molecules present. These results suggest that the presence of both albumin and
citrate combined are equal or better than Fe3+ added to apo transferrin in the absence of
any other molecules. Similar results for albumin and citrate were observed at the 10 mM
Pi level (supplemental Figure 2).

Discussion

This work examined serum molecules that are capable of inhibiting (Pi and
hydroxide) or stimulating (citrate and albumin) Fe3+ loading into apo transferrin. The
data support the hypothesis that the sheer abundance of albumin in serum, with its
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ability to bind metal ions (Fe3+) and organic acids (citrate) capable of coordinating to
Fe3+, are critical components that protect Fe3+ from reacting with Pi and allow time for
apo transferrin to bind Fe3+.

The in vitro reaction conditions used in this study that facilitated iron loading
into apo transferrin occurred when both albumin and citrate were present. In contrast,
the lack of albumin or citrate showed that Pi, even at physiologically normal
concentrations inhibited iron loading into apo transferrin.
Inflammation is linked with elevated LPI levels but the reason LPI forms with
inflammation is unknown. Our lab has proposed that some of the LPI that forms is a
soluble iron-phosphate complex23.

Based on the work by several groups16,36 we

speculated that citrate and albumin might act as mediator molecules to deliver Fe3+ to
apo transferrin in the presence of phosphate. This hypothesis is supported indirectly by
studies that show that inflammation and LPI formation occur under inflammatory
conditions that also correlate with decreased serum citrate levels28 and decreased serum
albumin levels18,36. In addition, in many of the inflammatory diseases such as diabetes
and kidney disease, Pi levels increase43–45.

We propose that the combination of

decreased concentrations of citrate and albumin with elevated Pi concentrations leads to
the inability of apo transferrin to compete with Pi for Fe3+ ions resulting in the
formation of Fe-Pi complexes23.

Thus, we propose that inflammation leads to LPI

formation through alterations of the concentrations of these molecules and proteins.
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In contrast to inflammation, exercise shows beneficial effects against
oxidative stress29,46,47. A potential reason that exercise might decrease oxidative stress is
that exercise increases citrate levels and serum albumin levels29,46–48.

The results

presented in this paper showed that citrate or albumin alone each improved Fe3+
loading into apo transferrin in the presence of phosphate. The combination of both
citrate and albumin further enhanced iron loading.
An important question to address moving forward relates to other
potential Fe3+ mediators in the serum and how their concentrations might affect Fe3+
loading into apo transferrin.

Adenosine tri-phosphate (ATP) and adenosine di-

phosphate (ADP) pyrophosphate (PPi) and other organic acids are all physiologically
relevant Fe3+ binding molecules49.

In fact, PPi delivers Fe3+ to apo transferrin50,51.

Human serum ATP and ADP concentrations range between 1 – 10 μM while human
serum PPi levels are around 3 μM [54] [55, 56]. The concentrations of ATP, ADP and
PPi are similar to the predicted normal LPI concentrations of about 1 μM6. At these
concentrations it is feasible to suggest that ATP, ADP and PPi might assist in mediating
Fe3+ to apo transferrin in serum.

However serum is still more complex than the

simplified system we have studied.

For example Ca2+ and Mg2+ are present at

approximately 1 mM concentrations in serum. Ca2+ is also precipitated by phosphate so
citrate, albumin, ATP, ADP and PPi are presumably involved in preventing this
precipitation reaction from occurring. In fact, serum PPi is a potent inhibitor of vascular
calcification52. Future studies will examine the roles of other potential Fe3+ chelating
molecules in apo transferrin iron loading as well as examining divalent metal
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competition reactions by adding Ca2+ and Mg2+ into the buffer system we have used to
mimic serum.
In summary, Schemes 4.1 and 4.2 show that properly coordinating Fe3+
with citrate or albumin or the combination of the two significantly enhances Fe3+
loading into apo-transferrin.

Therefore, interventions that help patients with

inflammatory conditions maintain normal citrate and albumin levels, such as exercise
and diet, might minimize the formation of LPI and decrease oxidative stress associated
with LPI in these diseases.
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Supplemental Figures

Supplemental figure 0.1 Competition of 10 mM phosphate and citrate for Fe3+ in an apo transferrin
iron-loading assay. Fe3+ ions were added to apo transferrin solutions containing (yellow) no phosphate
or citrate, (green) 10 mM Pi, (red) 10 mM Pi, 30 µM citrate, (blue) 10 mM Pi and 100 µM citrate. The
presence of 100 µM citrate is unable to restore Tf iron loading to the same level of Fe3+ ions alone but
significantly improves iron loading compared to reactions without citrate.
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Supplemental figure 0.2 Transferrin iron loading in the presence of albumin and citrate in 10 mM
phosphate. Fe3+ was added to an apo transferrin solution with: (yellow) no other molecules, (green) 10
mM Pi, (blue) 10 mM Pi and 2 g/dL albumin, (red) 10 mM Pi with 5 g/dL albumin, (purple) 10 mM Pi
with 5 g/dL albumin and 100 µM citrate).
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Supplemental figure 0.3A EDX analysis of Iron Phosphate nanoparticles from transferrin iron loading
experiments in the presence of 10 mM phosphate and 150 µM citrate. Panel A. Energy-dispersive X-ray
spectroscopy (XEDS) by TF-20 Transmission Electron Microscope 200KV. Representation of FePi complex
with the presence of Citrate. Phosphate (Pi) and Iron (Fe) peaks are minimal or non-existent due to lack of
FePi complex present in samples. Copper (Cu) as well as other metal peaks are present due to the
material in the grids.
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Supplemental figure 0.3B EDX analysis of Iron Phosphate nanoparticles from transferrin iron loading
experiments in the presence of 10 mM phosphate and no citrate. B. Energy-dispersive X-ray
spectroscopy (XEDS) representation of FePi complex formed without the presence of Citrate. Pi peak at
2Kev and 7500Ka counts. Fe peak at 6.25Kev and 2500Ka counts.
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